Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

t many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for the treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research an
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Many new dentists ... can do to ensure that their practice will be a ... the basic supplies they use the most can make all ... many dentists have recently discovered that purchasing discount dental ... According to successful dentists across ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources ... in the EU5 countries ( France , ... , Spain and the ... view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid ... robust uptake of Relvar as a first-line LABA/ICS FDC ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that Bruce Cozadd ... 35th Annual Health Care Conference on Monday, May 3, 2010 at ... Boston, MA. , , , ... of the presentation may be accessed from the Investors section of the Jazz ...
... April 26 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... announced Paul F. Truex , Anthera,s President and Chief Executive Officer ... Boston, MA on Monday, May 3, 2010 at ... , , ...
Cached Medicine Technology:Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference 2
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
(Date:7/24/2014)... SHAWNEE, Kan. (PRWEB) July 24, 2014 ... announces that it has achieved certification for ... as tested and verified by the DoD Information ... Acuo Vendor Neutral Archive, identified within the DoD ... the Authority to Operate designation from the U.S. ...
(Date:7/24/2014)... new study led by the Translational Genomics Research Institute ... and the immune system during HIV infection. , Currently, ... infect others based on their blood viral load. ... their semen despite having low levels in their blood. ... virus can be found in different parts of the ...
(Date:7/24/2014)... Atlanta, GA (PRWEB) July 24, 2014 ... Act on Tuesday, President Obama cited the Atlanta ... 35 model programs from across the country ( ... training as an essential pillar of U.S. economic ... replicated nationally. , “This recognition from President Obama ...
(Date:7/24/2014)... that it is possible to predict long-term cancer risk from ... same exposure. The findings, which currently appear in the journal ... simpler and cheaper tests to screen chemicals for their potential ... in incidence of and mortality from cancer, about 40 percent ... lifetime, and around 20 percent will die of it. Currently ...
Breaking Medicine News(10 mins):Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Researchers discover new way to determine cancer risk of chemicals 2
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
Collars can be attach to any Pulse aprons....
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
Medicine Products: